

June 2021 Draft

CHAPTER 61-04-15
LIMITED PRESCRIPTIVE AUTHORITY FOR TOBACCO CESSATION THERAPIES

Section

61-04-15-01 Definitions

61-04-15-02 Ordering of Tobacco Cessation Therapies

61-04-15-01. Definitions. For purposes of this chapter:

1. “ACPE” means the Accreditation Council for Pharmacy Education.
2. “Authorized Pharmacist” means a pharmacist who has successfully completed an appropriate study or training to meet the requirements in this rule.
3. “Statewide Protocol” refers to protocols developed by Board for the purpose of an authorized pharmacist ordering tobacco cessation therapies.

History: Effective October 1, 2021.

General Authority: NDCC 28-32-02, 43-15-10

Law Implemented: NDCC 23-01-42, 43-15-10(24)

61-04-15-02. Ordering of Tobacco Cessation Therapies.

1. Statewide Protocol
 - a. Prescriptive authority for tobacco cessation therapy shall be exercised solely in accordance with the statewide protocol approved by the Board
 - b. An authorized pharmacist exercising prescriptive authority must maintain and have readily available a current copy of the statewide protocol approved by the Board.
2. Education and Training
 - a. An authorized pharmacist must successfully complete a course of training accredited by ACPE in the subject area of tobacco cessation drug therapy.
 - b. Training must include study and instruction in the following content areas:
 - (1) Mechanisms of action for contraindications, drug interactions, and monitoring cessation.
 - (2) Current standards for prescribing tobacco cessation therapies.
 - (3) Identifying indications for the use of tobacco cessation therapies.
 - (4) Interviewing patient to establish need for tobacco cessation therapy.
 - (5) Counseling patient regarding the safety, efficacy, and potential adverse effects of drug products for tobacco cessation.
 - (6) Evaluating patient’s medical profile for drug interactions.
 - (7) Referring patient follow-up care with primary healthcare provider.
 - (8) Informed consent.
 - (9) Record management.
 - (10) Management of adverse events, including identification, appropriate response, documentation and reporting.
3. Authorized drugs. Prescriptive authority shall be limited to those drugs delineated in the statewide protocol approved by the Board which include prescription and non-prescription therapies.
4. Labeling. Tobacco cessation therapies ordered and dispensed must be labeled in accordance with section 61-04-06.
5. Reporting. As soon as reasonable possible, the authorized pharmacist shall notify the patient’s primary health care provider of the tobacco cessation therapy provided to the

patient. If the patient does not have a primary health care provider, the pharmacist may provide the patient with a record of the tobacco cessation therapy provided and shall advise the patient to consult a practitioner.

6. Records. An authorized pharmacist shall maintain records of the care provided and any tobacco cessation products ordered and dispensed pursuant to the statewide protocol. Informed consent must be documented in accordance with the statewide protocol. All records should be maintained for 5 years.

History: Effective October 1, 2021.

General Authority: NDCC 28-32-02, 43-15-10

Law Implemented: NDCC 23-01-42, 43-15-10(24)